Drug interactions Flashcards
Alcohol
- CNS depressans
- additive CNS depression, sedation, ataxia, increased risks of accidents
- Acetaminophen
- Increased formation of hepatotoxic metabolites of acetamonophen
Antacid
- Digoxin, iron supplements, fluoroquinolones, ketoconazole, tetracyclines, thyroxine
- Decreased gut absorption due to either to reaction with the affected drug or due to reduced acidity
Antihistamines
- Antimuscarinis, sedatives
- Additive effects with the drugs affected
Antimuscarnic drugs
- Drugs absorbed from the small intestine
- Slowed onset of effect because stomach emptying is delayed
Barbiturates (phenobarbital)
- Azoles, CCB, cyclosporine, propanol,protease inhibitors, quinidine, steroids, warfarin, kinase inhibitors, methadone, ansd many other drugs metabolzied in the liver
- Increased clearance of the affected drugs due to enzyme induction, possibly leading to decreases in drug effectiveness
Beta blockers
- Insulin
- masking of symptoms of hypoglycemia
- Prazosin
- increased first dose syncope
Bile acid-binding resins
- Acetaminophen, digitalis, thiazides, thyroxine
- Reduced abdorption of the affected drug
Carbamazepine
Cyclosporine, lidocaine, phenytoin, propanolol, quinidine, theophylline, warfarin, dofetilide
Reduced effect of other drugs because of induction of metabolism
Cimetidine
BZ, lidocaine, phenytoin, propanol, quinidine, theophylline, warfarin, dofetilide
Risk of toxicity due to inhibition of metabolism or reduced renal excretion
Disulfiram, metronidazole, certain cephalosporins
Ethanol
Increased hangover effect due to inhibition of aldehyde dehydrogenase
Erythromycin
Carbamazepine, cisaparide, quinidine, sildenafil, SSRIs
Risk of toxicity due to to inhibition of metabolism
Furanocoumarins (grapefruit)
Alprazolam, atorvastatin, cyclosporine, midazolam, nifedipine
Risk of toxicity due to inhibition of metabolism
ketoconazole and other azoles
Benzodiazepines, cisapride, cyclosporine, fluoxetine, lovastatin, omeprazole, quinidine, tolbutamide, oral anticoagulants (warfarin, apixaban, rivaroxaban)
Risk of toxicity due to inhibition of metabolism, Increased bleeding with oral anticoagulants, myopathy with statins
MAO inhibitors
- Catecholamine releasers (amphetamine, ephedrine)
- Increased norepinephrine in sympathetic nerve endings released by the interacting
- Tyramine-containing foods and beverages
- hypertensive crisis
NSAIDs
- Anticoagulants
- Increased bleeding tendency because of reduced platelt aggregation
- ACE inhibitors
- Decreased hypertensive efficacy of ACE inhibitor
- Loop diuretics
- reduced diuretic efficacy